MDGL
Madrigal Pharmaceuticals, Inc.NASDAQHealthcare$546.89+3.22%ClosedMarket Cap: $12.55B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
20.36
P/S
13.09
EV/EBITDA
-48.03
DCF Value
$3,107.85
FCF Yield
-1.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.1%
Operating Margin
-31.3%
Net Margin
-30.1%
ROE
-43.8%
ROA
-23.0%
ROIC
-31.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $321.1M | 92.4% | $-59.6M | $-58.6M | $-2.57 | — |
| FY 2025 | $958.4M | 94.1% | $-300.1M | $-288.3M | $-12.85 | — |
| Q3 2025 | $287.3M | 93.7% | $-114.0M | $-114.2M | $-5.08 | — |
| Q2 2025 | $212.8M | 95.7% | $-47.2M | $-42.3M | $-1.90 | — |
| Q1 2025 | $137.3M | 96.7% | $-79.3M | $-73.2M | $-3.32 | — |
| Q4 2024 | $103.3M | 96.7% | $-67.0M | $-59.4M | $-2.71 | — |
| FY 2024 | $180.1M | 96.5% | $-497.9M | $-465.9M | $-21.90 | — |
| Q3 2024 | $62.2M | 96.5% | $-116.3M | $-107.0M | $-4.92 | — |
| Q2 2024 | $14.6M | 95.7% | $-162.5M | $-152.0M | $-7.10 | — |
| Q1 2024 | $0.00 | NaN% | $-152.0M | $-147.5M | $-7.38 | — |
| Q4 2023 | $0.00 | NaN% | $-117.2M | $-112.2M | $-5.68 | — |
| FY 2023 | $0.00 | NaN% | $-380.5M | $-373.6M | $-19.99 | — |